Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KOTCC-1 model

Journal of Urology

Volumn 172, Issue 4 I, 2004, Pages 1485-1489

  Muramaki, Mototsugu ^a   Miyake, Hideaki ^a   Hara, Isao ^a   Kawabata, Gaku ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bladder; Bladder neoplasms; Gemcitabine; O (chloroacetylcarbamoyl)fumagillol

Indexed keywords

FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METASTASIS; MICROVASCULATURE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SUBCUTANEOUS TISSUE TUMOR; TUMOR GROWTH;

EID: 4544220102     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000133653.74536.43     Document Type: Article

References (20)

1. Thurman, S. A. and DeWeese, T. L.: Multimodality therapy for the treatment of muscle-invasive bladder cancer. Semin Urol Oncol, 18: 313, 2000
2. Saxman, S. B., Propert, K. J., Einhorn, L. H., Crawford, E. D., Tannock, I., Raghavan, D. et al: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol, 15: 2564, 1997
3. Heinemann, V.: Gemcitabine: progress in the treatment of pancreatic cancer. Oncology, 60: 8, 2001
4. von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J. et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 18: 3068, 2000
5. Hanahan, D. and Folkman, J.: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353, 1996
6. Bochner, B. H., Cote, R. J., Weidner, N., Groshen, S., Chen, S. C., Skinner, D. G. et al: Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst, 87: 1603, 1995
7. Allen, L. E. and Maher, P. A.: Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line. J Cell Physiol, 155: 368, 1993
8. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F. et al: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol, 143: 1255, 1993
9. Dickinson, A. J., Fox, S. B., Persad, R. A., Hollyer, J., Sibley, G. N. and Harris, A. L.: Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol, 74: 762, 1994
10. Sumi, Y., Muramatsu, H., Takei, Y., Hata, K., Ueda, M. and Muramatsu, T.: Midkine, a heparin-binding growth factor, promotes growth and glycosaminoglycan synthesis of endothelial cells through its action on smooth muscle cells in an artificial blood vessel model. J Cell Sci, 115: 2659, 2002
11. Streeter, E. H. and Harris, A. L.: Angiogenesis in bladder cancer-prognostic marker and target for future therapy. Surg Oncol, 11: 85, 2002
12. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H. et al: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature, 348: 555, 1990
13. Beecken, W. D., Fernandez, A., Panigrahy, D., Achilles, E. G., Kisker, O., Flynn, E. et al: Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice. Urology, 56: 521, 2000
14. Inoue, K., Chikazawa, M., Fukata, S., Yoshikawa, C. and Shuin, T.: Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. Clin Cancer Res, 9: 886, 2003
15. Herbst, R. S., Madden, T. L., Tran, H. T., Blumenschein, G. R., Jr., Meyers, C. A., Seabrooke, L. F. et al: Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol, 20: 4440, 2002
16. Miyake, H., Hara, I., Yamanaka, K., Gohji, K., Arakawa, S. and Kamidono, S.: Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells. Br J Cancer, 79: 1651, 1999
17. Fox, S. B., Leek, R. D., Weekes, M. P., Whitehouse, R. M., Gatter, K. C. and Harris, A. L.: Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol, 177: 275, 1995
18. Moscow, J. A., Morrow, C. S. and Cowan, K. H.: Multidrug resistance. Cancer Chemother Biol Response Modif, 13: 91, 1992
19. Boehm, T., Folkman, J., Browder, T. and O'Reilly, M. S.: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390: 404, 1997
20. Minischetti, M., Vacca, A., Ribatti, D., Iurlaro, M., Ria, R., Pellegrino, A. et al: TNP-470 and recombinant human interferon-alpha2a inhibit angiogenesis synergistically. Br J Haematol, 109: 829, 2000